4
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Toxicity of TNFα and platelet activating factor for human NT2N neurons: A tissue culture model for human immunodeficiency virus dementia

, &
Pages 118-126 | Received 09 Nov 1995, Accepted 25 Jan 1996, Published online: 10 Jul 2009
 

Abstract

A significant proportion of HIV-1 infected individuals develop a symptom complex consisting of dementia and motor deficits termed HIV Dementia (HTVD) or the AIDS Dementia complex (ADC). The pathophysiology of this neurologic complication is unclear, but neuronal injury and death may occur as a direct result of the release of cytokines from HIV-1 infected microglial cells (Everall et al, 1991). To evaluate the utility of a human neuronal cell line, NT2N, for studies of HTV-related neuronal cytotoxicity, we studied cellular viability after exposure to HIV-1 gp120, tumor necrosis factor α (TFNα), platelet activating factor (PAF), interleukin 1 beta (IL-1β), and interferon gamma (D7Nγ), all of which have been implicated in previous publications as having a role in HIVD (Brenneman et al, 1988; Dreyer ef al, 1990; Merrill ef al, 1992; Gelbard et al, 1993). Neither gp120 nor the cytokines IL-1β and IFNy resulted in significant NT2N cell death. However, TNFa and PAF were highly neurotoxic in this assay. Pentoxifylline, which inhibits the effects of TNFa, had a significant protective effect. This system provides an excellent subtrate for the evaluation of neurotoxicity and for the development of pharmacologic agents that may be useful in HIV dementia.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.